Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Ensartinib

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Ensartinib on our secure patient portal to submit your prescription, upload documents and track your approval status.

Ensartinib

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Ensartinib
Generic Name (API): Ensartinib Hydrochloride
Dosage Form & Strength: 25 mg, 100 mg
Route: Oral
Drug Class: ALK tyrosine kinase inhibitor

Manufacturer / Innovator:

Betta Pharmaceuticals Co., Ltd.

Regulatory Approval:

  • NMPA (China)
  • US FDA
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Ensartinib Used For?

Ensartinib is a once-daily capsule for adults with non-small cell lung cancer (NSCLC) whose tumour tests positive for an ALK gene change. It was developed by Betta Pharmaceuticals Co., Ltd. in Hangzhou together with its US subsidiary Xcovery Holdings, and is sold in China as 贝美纳 (Beimena®). Its research code was X-396.

China's National Medical Products Administration (NMPA) first approved it in November 2020 and has since added two more uses. According to Betta's announcements, the Chinese approvals now cover:

  • ALK-positive locally advanced or metastatic NSCLC, including people who have not had any ALK medicine before (added March 2022)
  • ALK-positive advanced NSCLC that has grown on, or could not be tolerated with, an earlier first-generation ALK tablet (the first approval, November 2020)
  • Treatment after surgery for ALK-positive NSCLC of stage IB to IIIB, once the tumour has been fully removed, with or without chemotherapy as the doctor decides (added September 2026)

An ALK-positive result has to come from a proper laboratory test on the tumour, so a lung cancer specialist will confirm this before suggesting it. Our lung cancer medicines page brings together other targeted options we help families import.

How It Works

In some lung cancers, mostly adenocarcinomas, a piece of the ALK gene becomes fused to another gene. The fused protein stays switched on and keeps telling the cancer cells to divide. This medicine is a tyrosine kinase inhibitor that blocks that ALK signal. In laboratory work it also acted against several ALK mutations that make tumours stop responding to older ALK medicines, and it reaches the brain, where this cancer often spreads.

What the Trials Showed

  • First treatment for advanced disease (eXalt3, 290 patients in 21 countries): compared with a comparison medicine from the first ALK generation, median time without progression was 25.8 months against 12.7 months. Among people with measurable brain tumours, the brain lesions shrank in 59% against 21% (US label figures).
  • After an earlier ALK tablet stopped working (phase 2 study at 27 Chinese centres): 52% of 147 assessable patients had their tumours shrink, and 70% of 40 patients with measurable brain metastases had a response in the brain.
  • After surgery (ELEVATE, 274 patients): at 2 years, 87.3% of patients taking it were alive without the cancer returning, against 57.2% on placebo, a cut of about 80% in the risk of recurrence. Survival data are not yet mature.

Recommended Dosage

  • Usual dose: 225 mg by mouth once a day, which is two 100 mg capsules plus one 25 mg capsule. This is the dose used in all three main trials and on the US label.
  • Food: the US label allows it with or without food; try to take it at about the same time each day
  • How to take it: swallow the capsules whole; do not open, crush, chew or dissolve them
  • Missed dose or vomiting: take a missed dose unless the next one is due within 12 hours, and never two doses on one day; if you vomit, wait for the next scheduled dose
  • Dose steps: if side effects need it, the dose drops to 200 mg and then 150 mg a day; if 150 mg is not tolerated, treatment stops
  • How long: for advanced disease, until it stops working or side effects become too much; after surgery, the ELEVATE trial gave it for up to 2 years

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Who should not take it: anyone with a severe allergy to the active substance or any ingredient. The US capsules contain the yellow dye tartrazine, which can trigger allergic-type reactions, including asthma, in people sensitive to aspirin; check the ingredient list on the Chinese pack with your pharmacist. The figures below come from the US prescribing information, which pooled 458 patients.

  • Skin rash and itching: the most frequent problem. Skin reactions affected 80% (14% severe), mainly rash (72%) and itching (32%). One case of a serious drug reaction with fever and organ involvement (DRESS) was reported. Sun sensitivity was rare, but limiting sun exposure is sensible.
  • Liver: ALT rose in 59% and AST in 58% of patients, usually mildly. Liver blood tests are done before starting and regularly during treatment.
  • Lung inflammation (pneumonitis): seen in 5%. New or worsening breathlessness, cough or fever must be reported straight away; if this is confirmed, the medicine is stopped for good.
  • Raised blood sugar: 44% had higher glucose readings. People with diabetes may need closer checks.
  • Muscle enzyme (CPK) rise: 43% of those tested. Unexplained muscle pain or weakness should be mentioned to the doctor.
  • Slow heartbeat: 6%, all mild or moderate. Pulse and blood pressure are checked, especially with heart medicines that also slow the heart.
  • Eyesight changes: 8% had blurred or altered vision; an eye check is advised if this happens.
  • High uric acid: 6%.

Other points: serious side effects occurred in 23% of patients in eXalt3, most often pneumonia. It is broken down by the liver enzyme CYP3A and carried by P-glycoprotein, so moderate or strong blockers or boosters of CYP3A, and P-glycoprotein blockers, should be avoided; always tell the oncologist about every other medicine and herbal product. It can harm an unborn baby. Women who could become pregnant and men with such partners should use effective contraception during treatment and for 1 week after the last dose, and breastfeeding should stop for the same period. Its safety in children has not been established.

How to Access Ensartinib in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Ensartinib to India?

Each supply is brought in for a single named patient, requested either by the family or by the treating hospital, under India's rules for importing unapproved medicines. Please keep these ready:

  • A prescription from an oncologist or chest physician stating the dose
  • The biopsy report and the ALK test result (IHC, FISH or a next-generation sequencing report)
  • Recent scans and the stage of disease, or the surgery report if it is for use after an operation
  • Recent liver and kidney tests, blood sugar and details of any earlier lung cancer treatment
  • Government-issued photo ID of the patient

How is the order confirmed?

Once we have checked a valid prescription and, where required, the import permit has been issued.

Is Ensartinib available in India?

No. CDSCO has not approved it, so Indian pharmacies do not stock it. Outside China it is approved by the US FDA (as Ensacove®, December 2024), and Betta announced in November 2026 that the European Commission had also authorised it.

A patient can still receive it through the Named Patient Program (NPP), which lets a medicine without Indian registration be imported for one person on a doctor's prescription. We also help with other China-approved ALK inhibitors, for example iruplinalkib capsules.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. It is a capsule kept at room temperature, not in a fridge; the US label specifies 20°C to 25°C in the original bottle with its moisture-absorbing desiccant, and we follow the storage line printed on the Chinese pack. Boxes travel sealed under temperature-controlled shipping so they are not exposed to heat or damp on the way. Because the daily dose combines two strengths, each order includes both the 100 mg and 25 mg capsules in the right numbers. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

ALK-positive lung cancer is often treated for several years with a daily capsule, so a steady supply matters. When the prescription and permit are in place, we deliver to the cities listed here and to many other towns.

Delhi

Thoracic oncology clinics in Delhi can send the ALK test report in the morning, and dispatch from New Delhi keeps the wait short.

Mumbai

For patients in Mumbai, we can deliver to the hospital where the brain and chest scans are reviewed, or to home.

Bangalore

Lung cancer patients in Bangalore get a clear count of 100 mg and 25 mg capsules for each month, so the two strengths never run short at different times.

Chennai

In Chennai, we time each parcel around the liver and blood sugar checks the oncologist has planned.

Hyderabad

Surgeons and oncologists in Hyderabad can request it for a patient starting treatment after a lung operation.

Kolkata

Families in Kolkata and the north-east get courier tracking details by message for every monthly box.

Pune

For Pune, we keep the next month's capsules moving before the current supply runs low, since doses should not be skipped.

Ahmedabad

Chest physicians in Ahmedabad can share the NGS or FISH report, and we tell them which papers are still pending.

Vellore

Patients reviewed at hospitals in Vellore can collect the boxes at the hospital pharmacy during their visit.

Chandigarh

Patients from Punjab, Haryana and Himachal treated in Chandigarh can have supplies sent ahead of each scan review.

Lucknow

In Lucknow, delivery can go to the patient's home or to the cancer institute handling follow-up.

Kochi

Across Kerala, parcels are sent to Kochi or the town nearest the patient, packed to stay dry in the monsoon.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 20 November 2026

More Oncology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP